Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial

Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial - G-CSF therapy for spinal cord lesion-related neuropathic pain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012486

Enrollment

Registered

2014-01-22

Start date

2014-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord lesion-related neuropathic pain syndrome

Interventions

Granulocyte colony-stimulating factor (5 micro g/kg/d dissolved in 100ml of normal saline for 5 days, div.) Granulocyte colony-stimulating factor (10 micro g/kg/d dissolved in 100ml of normal saline f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Spinal cord lesion-related neuropathic pain patients with at least 3 Months history. 2. Patients who did not respond conventional drug treatments. 3. Patients who are not scheduled for spinal surgery. 4. Definitive image or history of spinal cord lesions. 5. Patients who agree with the participation in the present trial with printed informed consent. 6. Patients who can participate the present trial for 6 Month.

Exclusion criteria

Exclusion criteria: 1. Allergy for drugs to be tested. 2. History of hematologic malignancy. 3. Recent history (~5 years) of malignant disease. 4. Acute myocardial infarction or angina pectoris under treatment. 5. History or tendency of thorombosis or thoromboembolism. 6. Splenomegary. 7. Consciousness diorder. 8. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Pain reduction 1 month after drug administration (evaluated by numerical rating scale)	—

Secondary

Measure	Time frame
1. ratio of the patients showing 30% or 50% pain reduction 1 month after drug administration 2. Alteration of the score of Neuropathic pain symptoms inventory 3. Quantitative evaluation for neuropathic pain 4. QOL measure (EQ-5D)	—

Countries

Japan

Contacts

Public ContactYukiko Matsumoto

Chiba University Graduate School of Medicine Department of Orthopedics

chibaseikei8f@yahoo.co.jp043-226-2961

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026